Related Experiment Videos
Summary
Intravenous verapamil can cause dangerous bradycardia and hypotension in infants with supraventricular tachycardia. Safer alternatives like digoxin and cardioversion are recommended for treating this condition in neonates and young infants.
Area of Science:
- Pediatric Cardiology
- Neonatal Pharmacology
Background:
- Supraventricular tachycardia (SVT) is a common arrhythmia in infants.
- Current treatment guidelines for infant SVT vary, with some including intravenous verapamil.
Observation:
- Two infants receiving intravenous verapamil for SVT experienced severe bradycardia and hypotension.
- No other predisposing factors for these adverse events were identified.
Findings:
- Direct cardiotoxic effects of intravenous verapamil are strongly implicated in these cases.
- Published literature indicates similar adverse events associated with verapamil in pediatric populations.
Implications:
- Intravenous verapamil administration should be avoided in neonates and young infants with SVT.
- Digoxin and cardioversion are presented as safer therapeutic options for infant SVT.
- This study highlights the critical need for cautious drug selection in pediatric critical care.